Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of the CAG regimen in relapsed or refractory T-cell acute lymphoblastic leukemia / T-lymphoblastic lymphoma
ChiCTR1900023581Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cytarabine, aclarubicin and granulocyte colony-stimulating factor in t-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: One-cycle complete remission or complete remission with incomplete hematologic recovery rate. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
cytarabineaclarubicingranulocyte colony-stimulating factor
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on ChiCTR1900023581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023581.